The future of cancer immunotherapy: microenvironment-targeting combinations

By Y. Murciano-Goroff, A. B. Warner, J. Wolchok. Cell Research, 2020

621 citations recorded by the source corpus.

Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer and its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories of approaches to the design of novel drugs and combination therapies: the first involves direct modification of the tumor, while the second indirectly enhances immunogenicity through alteration of the microenvironment. By systematically addressing the factors that mediate resistance, we are able to identify mechanistically-driven novel approaches to improve immunotherapy outcomes.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/e45faa7ac36c53200bb9b7cdcc0b41302c029c64

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. A. Dey
  2. Arvind K. Singh Chandel
  3. Rupa Sanyal
  4. Amarnath Mishra
  5. D. Pandey
  6. V. De Falco
  7. Arun Prakash Upadhyay
  8. J. M. Pérez de la Lastra

Citations in the corpus